Jeff Musgnung, MS | Psychiatrist.com

Article

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder

February 5, 2015

Here, review results from a post hoc analysis that evaluated the tolerability of long-term desvenlafaxine for major depressive disorder at discontinuation using a taper regimen compared with abrupt discontinuation.Â

Philip T. Ninan, Christine J. Guico-Pabia, Gina Buckley, et al

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

October 15, 2013

Susan G. Kornstein, Philip T. Ninan, Boadie W. Dunlop, et al

Original Research

A Pooled Analysis of Gender and Trauma-Type Effects on Responsiveness to Treatment of PTSD With Venlafaxine Extended Release or Placebo

October 31, 2008

Dan J. Stein, Barbara O. Rothbaum, Jonathan R. T. Davidson, et al

Original Research

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

August 15, 2007

David L. Dunner, Susan G. Kornstein, Alan F. Schatzberg, et al

Original Research

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

July 16, 2007

David L. Dunner, Susan G. Kornstein, Alan F. Schatzberg, et al

Original Research

Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder

January 16, 2006

Jeff Musgnung, Isma Benattia, Jay Graepel, et al